-+ 0.00%
-+ 0.00%
-+ 0.00%

aTyr Pharma Advances ATYR0101 To IND Candidate Stage For Pulmonary Fibrosis; Preclinical Data Demonstrate ATYR0101's Unique Anti-fibrotic Mechanism Through Interaction With LTBP-1

Benzinga·05/14/2025 12:07:57
Listen to the news

Preclinical data demonstrate ATYR0101's unique anti-fibrotic mechanism through interaction with LTBP-1.

ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit.

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has advanced its next investigational new drug (IND) candidate, ATYR0101, which has been selected to be showcased in an oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit, which is scheduled to take place May 16 – 17, 2025, in San Francisco, CA.

The presentation will feature preclinical data generated to date for ATYR0101, a fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase (DARS) that binds to latent transforming growth factor beta binding protein 1 (LTBP-1) to induce cell death of myofibroblasts, which are key cells responsible for driving the progression of fibrosis.